Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 485042, 12 pages
http://dx.doi.org/10.1155/2012/485042
Review Article

Alkaloids Isolated from Natural Herbs as the Anticancer Agents

State Key Laboratory of Quality Research in Chinese Medicine (University of Macau) and Institute of Chinese Medical Sciences, University of Macau, Avenue Padre Toma’s Pereira, Taipa 999078, Macao, China

Received 11 May 2012; Revised 17 July 2012; Accepted 30 July 2012

Academic Editor: Alvin J. Beitz

Copyright © 2012 Jin-Jian Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. T. Wang and G. Y. Liang, Zhong Yao Hua Xue, Shanghai Scientific & Technical, 2009.
  2. M. R. Lee, “The history of Ephedra (ma-huang),” Journal of the Royal College of Physicians of Edinburgh, vol. 41, no. 1, pp. 78–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Benyhe, “Morphine: new aspects in the study of an ancient compound,” Life Sciences, vol. 55, no. 13, pp. 969–979, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Li, Y. Shao, L. Hu et al., “BM6, a new semi-synthetic Vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles,” Cancer Biology and Therapy, vol. 6, no. 5, pp. 787–794, 2007. View at Google Scholar · View at Scopus
  5. M. Huang, H. Gao, Y. Chen et al., “Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo,” Clinical Cancer Research, vol. 13, no. 4, pp. 1298–1307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Chen, H. ZHao, X. Wang, F. S. C. Lee, H. Yang, and L. Zheng, “Analysis of major alkaloids in Rhizoma coptidis by capillary electrophoresis-electrospray-time of flight mass spectrometry with different background electrolytes,” Electrophoresis, vol. 29, no. 10, pp. 2135–2147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. H. Yu, K. J. Kim, J. D. Cha et al., “Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus,” Journal of Medicinal Food, vol. 8, no. 4, pp. 454–461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. C. W. Lau, X. Q. Yao, Z. Y. Chen, W. H. Ko, and Y. Huang, “Cardiovascular actions of berberine,” Cardiovascular Drug Reviews, vol. 19, no. 3, pp. 234–244, 2001. View at Google Scholar · View at Scopus
  9. J. Han, H. Lin, and W. Huang, “Modulating gut microbiota as an anti-diabetic mechanism of berberine,” Medical Science Monitor, vol. 17, no. 7, pp. RA164–RA167, 2011. View at Google Scholar · View at Scopus
  10. S. K. Kulkarni and A. Dhir, “Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders,” Phytotherapy Research, vol. 24, no. 3, pp. 317–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. B. Ji, Active Ingredients of Traditional Chinese Medicine: Pharmacology and Application, People's Medical Publishing Hourse Cp., LTD, 2011.
  12. Y. Sun, K. Xun, Y. Wang, and X. Chen, “A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs,” Anti-Cancer Drugs, vol. 20, no. 9, pp. 757–769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. V. Diogo, N. G. Machado, I. A. Barbosa, T. L. Serafim, A. Burgeiro, and P. J. Oliveira, “Berberine as a promising safe anti-cancer agent—is there a role for mitochondria?” Current Drug Targets, vol. 12, no. 6, pp. 850–859, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Tan, J. Lu, M. Huang et al., “Anti-cancer natural products isolated from chinese medicinal herbs,” Chinese Medicine, vol. 6, no. 1, p. 27, 2011. View at Google Scholar
  15. K. S. Eom, H. J. Kim, H. S. So, R. Park, and T. Y. Kim, “Berberine-induced apoptosis in human glioblastoma T98G Cells Is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction,” Biological and Pharmaceutical Bulletin, vol. 33, no. 10, pp. 1644–1649, 2010. View at Google Scholar · View at Scopus
  16. A. Burgeiro, C. Gajate, E. H. Dakir, J. A. Villa-Pulgarín, P. J. Oliveira, and F. Mollinedo, “Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells,” Anti-Cancer Drugs, vol. 22, no. 6, pp. 507–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Wang, Y. Feng, M. Zhu et al., “Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism,” Journal of Cellular Biochemistry, vol. 111, no. 6, pp. 1426–1436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. S. S. Chang, C. Gao, and L. C. Wang, “Berberine-induced morphologic differentiation and down-regulation of c-Ki-ras2 protooncogene expression in human teratocarcinoma cells,” Cancer Letters, vol. 55, no. 2, pp. 103–108, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Tang, D. Wang, C. Duan et al., “Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting rho kinase-mediated ezrin phosphorylation at threonine 567,” Journal of Biological Chemistry, vol. 284, no. 40, pp. 27456–27466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. T. Ho, J. S. Yang, T. C. Li et al., “Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9,” Cancer Letters, vol. 279, no. 2, pp. 155–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Jie, H. Li, Y. Tian et al., “Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro,” Journal of Gastroenterology and Hepatology, vol. 26, no. 1, pp. 179–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. T. P. Hamsa and G. Kuttan, “Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators,” Drug and Chemical Toxicology, vol. 35, no. 1, pp. 57–70, 2012. View at Google Scholar
  23. M. J. Youn, H. S. So, H. J. Cho et al., “Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells,” Biological and Pharmaceutical Bulletin, vol. 31, no. 5, pp. 789–795, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Hur, M. S. Hyun, S. Y. Lim, W. Y. Lee, and D. Kim, “The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells,” Journal of Cellular Biochemistry, vol. 107, no. 5, pp. 955–964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Manoharan, G. Sindhu, V. Vinothkumar et al., “Berberine prevents 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis: a biochemical approach,” European Journal of Cancer Prevention, vol. 21, no. 2, pp. 182–192, 2012. View at Google Scholar
  26. X. L. Li, Y. J. Hu, H. Wang et al., “Molecular spectroscopy evidence for berberine binding to DNA: comparative binding and thermodynamic profile of intercalation,” Biomacromolecules, vol. 13, no. 3, pp. 873–880, 2012. View at Google Scholar
  27. M. M. Islam and G. Suresh Kumar, “RNA-binding potential of protoberberine alkaloids: spectroscopic and calorimetric studies on the binding of berberine, palmatine, and coralyne to protonated RNA structures,” DNA and Cell Biology, vol. 28, no. 12, pp. 637–650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. K. Mantena, S. D. Sharma, and S. K. Katiyar, “Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 296–308, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. P. Hamsa and G. Kuttan, “Berberine inhibits pulmonary metastasis through down-regulation of MMP in metastatic B16F-10 melanoma cells,” Phytotherapy Research, vol. 26, no. 4, pp. 568–578, 2011. View at Google Scholar
  30. T. Singh, M. Vaid, N. Katiyar, S. Sharma, and S. K. Katiyar, “Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E and prostaglandin E receptors,” Carcinogenesis, vol. 32, no. 1, pp. 86–92, 2011. View at Google Scholar · View at Scopus
  31. Y. Kobayashi, Y. Nakano, M. Kizaki, K. Hoshikuma, Y. Yokoo, and T. Kamiya, “Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist,” Planta Medica, vol. 67, no. 7, pp. 628–633, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Kobayashi, “The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice,” Planta Medica, vol. 69, no. 5, pp. 425–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. W. Shin, E. A. Bae, X. F. Cai, J. J. Lee, and D. H. Kim, “In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents,” Biological and Pharmaceutical Bulletin, vol. 30, no. 1, pp. 197–199, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. H. C. Ko, Y. H. Wang, K. T. Liou et al., “Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells,” European Journal of Pharmacology, vol. 555, no. 2-3, pp. 211–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ogasawara, T. Matsubara, and H. Suzuki, “Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells,” Biological and Pharmaceutical Bulletin, vol. 24, no. 8, pp. 917–920, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ogasawara, T. Matsunaga, S. Takahashi, I. Saiki, and H. Suzuki, “Anti-invasive and metastatic activities of evodiamine,” Biological and Pharmaceutical Bulletin, vol. 25, no. 11, pp. 1491–1493, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. X. F. Fei, B. X. Wang, T. J. Li et al., “Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells,” Cancer Science, vol. 94, no. 1, pp. 92–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zhang, L. J. Wu, S. I. Tashiro, S. Onodera, and T. Ikejima, “Intracellular regulation of evodiamine-induced A375-S2 cell death,” Biological and Pharmaceutical Bulletin, vol. 26, no. 11, pp. 1543–1547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. K. G. Shyu, S. Lin, C. C. Lee et al., “Evodiamine inhibits in vitro angiogenesis: implication for antitumorgenicity,” Life Sciences, vol. 78, no. 19, pp. 2234–2243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. T. J. Lee, E. J. Kim, S. Kim et al., “Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2398–2407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Wang, S. Li, and M. W. Wang, “Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-κB signaling pathways and augmented by ubiquitin-proteasome inhibition,” Toxicology in Vitro, vol. 24, no. 3, pp. 898–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Yang, L. J. Wu, S. I. Tashino, S. Onodera, and T. Ikejima, “Reactive oxygen species and nitric oxide regulate mitochondriadependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells,” Free Radical Research, vol. 42, no. 5, pp. 492–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Zhang, Q. H. Zhang, L. J. Wu, S. I. Tashiro, S. Onodera, and T. Ikejima, “Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa,” Journal of Asian Natural Products Research, vol. 6, no. 1, pp. 19–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. C. H. Liao, S. L. Pan, J. H. Guh et al., “Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo,” Carcinogenesis, vol. 26, no. 5, pp. 968–975, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. H. P. Tsai, L. W. Lin, Z. Y. Lai et al., “Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors,” Journal of Biomedical Science, vol. 17, no. 1, article 49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. F. Chan, W. S. Chang, L. M. Chen et al., “Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity,” Molecules, vol. 14, no. 4, pp. 1342–1352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Dong, C. Sheng, S. Wang, Z. Miao, J. Yao, and W. Zhang, “Selection of evodiamine as a novel topoisomerase i inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents,” Journal of Medicinal Chemistry, vol. 53, no. 21, pp. 7521–7531, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. F. Kan, W. J. Huang, L. C. Lin, and P. S. Wang, “Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP,” International Journal of Cancer, vol. 110, no. 5, pp. 641–651, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. C. Huang, J. H. Guh, and C. M. Teng, “Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes,” Life Sciences, vol. 75, no. 1, pp. 35–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Yang, L. J. Wu, S. I. Tashino, S. Onodera, and T. Ikejima, “Critical roles of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis,” Free Radical Research, vol. 41, no. 10, pp. 1099–1108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Lai, X. W. He, Y. Jiang, and F. Chen, “Preparative separation and determination of matrine from the Chinese medicinal plant Sophora flavescens Ait by molecularly imprinted solid-phase extraction,” Analytical and Bioanalytical Chemistry, vol. 375, no. 2, pp. 264–269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. X. Li, R. Zhou, P. Zheng et al., “Cardioprotective effect of matrine on isoproterenol-induced cardiotoxicity in rats,” Journal of Pharmacy and Pharmacology, vol. 62, no. 4, pp. 514–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Xing, F. Yan, Y. Liu, Y. Liu, and Y. Zhao, “Matrine inhibits 3T3-L1 preadipocyte differentiation associated with suppression of ERK1/2 phosphorylation,” Biochemical and Biophysical Research Communications, vol. 396, no. 3, pp. 691–695, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Zheng, P. Zheng, X. Zhou et al., “Relaxant effects of matrine on aortic smooth muscles of guinea pigs,” Biomedical and Environmental Sciences, vol. 22, no. 4, pp. 327–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Long, X. T. Lin, K. L. Zeng, and L. Zhang, “Efficacy of intramuscular matrine in the treatment of chronic hepatitis B,” Hepatobiliary and Pancreatic Diseases International, vol. 3, no. 1, pp. 69–72, 2004. View at Google Scholar · View at Scopus
  56. B. Zhang, Z. Y. Liu, Y. Y. Li et al., “Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice,” European Journal of Pharmaceutical Sciences, vol. 44, no. 5, pp. 573–579, 2011. View at Google Scholar
  57. Y. Han, S. Zhang, J. Wu et al., “Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway,” Leukemia and Lymphoma, vol. 51, no. 7, pp. 1337–1346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Zhang, T. Wang, X. Wen et al., “Effect of matrine on HeLa cell adhesion and migration,” European Journal of Pharmacology, vol. 563, no. 1–3, pp. 69–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. J. Dai, J. Gao, Z. Z. Ji et al., “Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 91–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Liu, Y. Song, H. Chen, S. Pan, and X. Sun, “Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo,” Biological and Pharmaceutical Bulletin, vol. 33, no. 10, pp. 1740–1745, 2010. View at Google Scholar · View at Scopus
  61. C. Z. Liang, J. K. Zhang, Z. Shi, B. Liu, C. Q. Shen, and H. M. Tao, “Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 2, pp. 317–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Zhang, Z. Wang, T. Chong et al., “Matrine inhibits proliferation and induces apoptosis of the androgenindependent prostate cancer cell line PC-3,” Molecular Medicine Reports, vol. 5, no. 3, pp. 783–787, 2012. View at Google Scholar
  63. Z. Zhang, X. Wang, W. Wu et al., “Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD),” Phytotherapy research, vol. 26, no. 6, pp. 932–937, 2011. View at Google Scholar
  64. H. Jiang, C. Hou, S. Zhang et al., “Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells,” European Journal of Pharmacology, vol. 559, no. 2-3, pp. 98–108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Q. Zhang, Y. M. Li, T. Liu et al., “Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy,” World Journal of Gastroenterology, vol. 16, no. 34, pp. 4281–4290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Zhang, Y. Li, X. Chen et al., “Autophagy is involved in anticancer effects of matrine on SGC-7901 human gastric cancer cells,” Oncology Reports, vol. 26, no. 1, pp. 115–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. L. P. Zhang, J. K. Jiang, J. W. O. Tam et al., “Effects of Matrine on proliferation and differentiation in K-562 cells,” Leukemia Research, vol. 25, no. 9, pp. 793–800, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Li, G. Tan, X. Jiang et al., “Therapeutic effects of matrine on primary and metastatic breast cancer,” American Journal of Chinese Medicine, vol. 38, no. 6, pp. 1115–1130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Ma, S. Wen, Y. Zhan, Y. He, X. Liu, and J. Jiang, “Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells,” Planta Medica, vol. 74, no. 3, pp. 245–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Zhang, B. T. Dai, and Y. H. Xu, “Effects of matrine on invasion and metastasis of leukemia cell line Jurkat,” Zhongguo Zhong xi yi jie he za zhi, vol. 28, no. 10, pp. 907–911, 2008. View at Google Scholar · View at Scopus
  71. P. Yu, Q. Liu, K. Liu, K. Yagasaki, E. Wu, and G. Zhang, “Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-κB signaling,” Cytotechnology, vol. 59, no. 3, pp. 219–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. H. B. Yu, H. F. Zhang, D. Y. Li, X. Zhang, H. Z. Xue, and S. H. Zhao, “Matrine inhibits matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells,” Journal of Asian Natural Products Research, vol. 13, no. 3, pp. 242–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Luo, H. J. Zhong, L. M. Zhu et al., “Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism,” Molecular Biology Reports, vol. 39, no. 5, pp. 5459–5464, 2011. View at Google Scholar
  74. A. Szallasi, “Piperine: researchers discover new flavor in an ancient spice,” Trends in Pharmacological Sciences, vol. 26, no. 9, pp. 437–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Srinivasan, “Black pepper and its pungent principle-piperine: a review of diverse physiological effects,” Critical Reviews in Food Science and Nutrition, vol. 47, no. 8, pp. 735–748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. G. S. Bae, M. S. Kim, W. S. Jung et al., “Inhibition of lipopolysaccharide-induced inflammatory responses by piperine,” European Journal of Pharmacology, vol. 642, no. 1–3, pp. 154–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. S. A. Lee, S. S. Hong, X. H. Han et al., “Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity,” Chemical and Pharmaceutical Bulletin, vol. 53, no. 7, pp. 832–835, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Li, C. Wang, M. Wang, W. Li, K. Matsumoto, and Y. Tang, “Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms,” Life Sciences, vol. 80, no. 15, pp. 1373–1381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Krishnakumar, S. Manoharan, P. R. Palaniappan, P. Venkatachalam, and M. G. A. Manohar, “Chemopreventive efficacy of piperine in 7,12-dimethyl benz [a] anthracene (DMBA)-induced hamster buccal pouch carcinogenesis: an FT-IR study,” Food and Chemical Toxicology, vol. 47, no. 11, pp. 2813–2820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Selvendiran, S. M. Banu, and D. Sakthisekaran, “Oral supplementation of piperine leads to altered phase II enzymes and reduced DNA damage and DNA-protein cross links in Benzo(a)pyrene induced experimental lung carcinogenesis,” Molecular and Cellular Biochemistry, vol. 268, no. 1-2, pp. 141–147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Selvendiran and D. Sakthisekaran, “Chemopreventive effect of piperine on modulating lipid peroxidation and membrane bound enzymes in benzo(a)pyrene induced lung carcinogenesis,” Biomedicine and Pharmacotherapy, vol. 58, no. 4, pp. 264–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Selvendiran, C. Thirunavukkarasu, J. P. V. Singh, R. Padmavathi, and D. Sakthisekaran, “Chemopreventive effect of piperine on mitochondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice,” Molecular and Cellular Biochemistry, vol. 271, no. 1-2, pp. 101–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Selvendiran, J. P. V. Singh, K. B. Krishnan, and D. Sakthisekaran, “Cytoprotective effect of piperine against benzo[a]pyrene induced lung cancer with reference to lipid peroxidation and antioxidant system in Swiss albino mice,” Fitoterapia, vol. 74, no. 1-2, pp. 109–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Khajuria, N. Thusu, U. Zutshi, and K. L. Bedi, “Piperine modulation of carcinogen induced oxidative stress in intestinal mucosa,” Molecular and Cellular Biochemistry, vol. 189, no. 1-2, pp. 113–118, 1998. View at Google Scholar · View at Scopus
  85. S. Manoharan, S. Balakrishnan, V. P. Menon, L. M. Alias, and A. R. Reena, “Chemopreventive & efficacy of curcumin and piperine during 7,12-dimethylbenz [a]anthracene-induced hamster buccal pouch carcinogenesis,” Singapore Medical Journal, vol. 50, no. 2, pp. 139–146, 2009. View at Google Scholar · View at Scopus
  86. D. P. Bezerra, F. O. Castro, A. P. N. N. Alves et al., “In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from piper,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 6, pp. 801–807, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Kakarala, D. E. Brenner, H. Korkaya et al., “Targeting breast stem cells with the cancer preventive compounds curcumin and piperine,” Breast Cancer Research and Treatment, vol. 122, no. 3, pp. 777–785, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. L. H. Lai, Q. H. Fu, Y. Liu et al., “Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model,” Acta Pharmacologica Sinica, vol. 33, no. 4, pp. 523–530, 2012. View at Google Scholar
  89. Q. F. Song, Y. C. Qu, H. B. Zheng, G. H. Zhang, H. G. Lin, and J. L. Yang, “Differentiation of erythroleukemia K562 cells induced by piperine,” Ai Zheng, vol. 27, no. 6, pp. 571–574, 2008. View at Google Scholar · View at Scopus
  90. C. R. Pradeep and G. Kuttan, “Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice,” Clinical and Experimental Metastasis, vol. 19, no. 8, pp. 703–708, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. P. Hwang, H. J. Yun, H. G. Kim et al., “Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCα/ERK1/2-dependent matrix metalloproteinase-9 expression,” Toxicology Letters, vol. 203, no. 1, pp. 9–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. C. R. Pradeep and G. Kuttan, “Piperine is a potent inhibitor of nuclear factor-κB (NF-κB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells,” International Immunopharmacology, vol. 4, no. 14, pp. 1795–1803, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. R. K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S. K. Gupta, and M. F. Fromm, “Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 2, pp. 645–650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Li, Y. Lei, Y. Jia, N. Li, M. Wink, and Y. Ma, “Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells,” Phytomedicine, vol. 19, no. 1, pp. 83–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Makhov, K. Golovine, D. Canter et al., “Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity,” Prostate, vol. 72, no. 6, pp. 661–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. G. B. Mahady and C. W. W. Beecher, “Quercetin-induced benzophenanthridine alkaloid production in suspension cell cultures of Sanguinaria canadensis,” Planta Medica, vol. 60, no. 6, pp. 553–557, 1994. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Vavrečková, I. Gawlik, and K. Müller, “Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism,” Planta Medica, vol. 62, no. 5, pp. 397–401, 1996. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Lenfeld, M. Kroutil, and E. Marsalek, “Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus,” Planta Medica, vol. 43, no. 2, pp. 161–165, 1981. View at Google Scholar · View at Scopus
  99. T. K. Beuria, M. K. Santra, and D. Panda, “Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly a bundling,” Biochemistry, vol. 44, no. 50, pp. 16584–16593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. J. H. Jeng, H. L. Wu, B. R. Lin et al., “Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production,” Atherosclerosis, vol. 191, no. 2, pp. 250–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Ahsan, S. Reagan-Shaw, J. Breur, and N. Ahmad, “Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins,” Cancer Letters, vol. 249, no. 2, pp. 198–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. M. C. Chang, C. P. Chan, Y. J. Wang et al., “Induction of necrosis and apoptosis to KB cancer cells by sanguinarine is associated with reactive oxygen species production and mitochondrial membrane depolarization,” Toxicology and Applied Pharmacology, vol. 218, no. 2, pp. 143–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Debiton, J. C. Madelmont, J. Legault, and C. Barthomeuf, “Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion,” Cancer Chemotherapy and Pharmacology, vol. 51, no. 6, pp. 474–482, 2003. View at Google Scholar · View at Scopus
  104. A. R. Hussain, N. A. Al-Jomah, A. K. Siraj et al., “Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells,” Cancer Research, vol. 67, no. 8, pp. 3888–3897, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Kim, T. J. Lee, J. Leem, S. C. Kyeong, J. W. Park, and K. K. Taeg, “Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL,” Journal of Cellular Biochemistry, vol. 104, no. 3, pp. 895–907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. V. M. Adhami, M. H. Aziz, H. Mukhtar, and N. Ahmad, “Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes,” Clinical Cancer Research, vol. 9, no. 8, pp. 3176–3182, 2003. View at Google Scholar · View at Scopus
  107. V. M. Adhami, M. H. Aziz, S. R. Reagan-Shaw, M. Nihal, H. Mukhtar, and N. Ahmad, “Sanguinarine causes cell cyle blockade and apoptosis of human prostate carcinoma cells via modulation of cylin kinase inhibitor-cyclin-cyclin-dependent kinase machinery,” Molecular Cancer Therapeutics, vol. 3, no. 8, pp. 933–940, 2004. View at Google Scholar · View at Scopus
  108. P. Weerasinghe, S. Hallock, S. C. Tang, B. Trump, and A. Liepins, “Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells,” Experimental and Toxicologic Pathology, vol. 58, no. 1, pp. 21–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. I. De Stefano, G. Raspaglio, G. F. Zannoni et al., “Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma,” Biochemical Pharmacology, vol. 78, no. 11, pp. 1374–1381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. H. Choi, W. Y. Choi, S. H. Hong et al., “Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Huh, A. Liepins, J. Zielonka, C. Andrekopoulos, B. Kalyanaraman, and A. Sorokin, “Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity,” Cancer Research, vol. 66, no. 7, pp. 3726–3736, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Ahsan, S. Reagan-Shaw, D. M. Eggert et al., “Protective effect of sanguinarine on ultraviolet B-mediated damages in SKH-1 hairless mouse skin: implications for prevention of skin cancer,” Photochemistry and Photobiology, vol. 83, no. 4, pp. 986–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. B. C. Jang, J. G. Park, D. K. Song et al., “Sanguinarine induces apoptosis in A549 human lung cancer cells primarily via cellular glutathione depletion,” Toxicology in Vitro, vol. 23, no. 2, pp. 281–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. Y. J. Cai, J. J. Lu, H. Zhu et al., “Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition,” Free Radical Biology and Medicine, vol. 45, no. 5, pp. 627–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. Y. Cai, J. Lu, Z. Miao, L. Lin, and J. Ding, “Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells,” Cancer Biology and Therapy, vol. 6, no. 11, pp. 1794–1799, 2007. View at Google Scholar · View at Scopus
  116. A. Vogt, A. Tamewitz, J. Skoko, R. P. Sikorski, K. A. Giuliano, and J. S. Lazo, “The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1,” Journal of Biological Chemistry, vol. 280, no. 19, pp. 19078–19086, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Lopus and D. Panda, “The benzophenanthridine alkaloid sanguinarine perturbs microtubule assembly dynamics through tubulin binding: a possible mechanism for its antiproliferative activity,” FEBS Journal, vol. 273, no. 10, pp. 2139–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Holy, G. Lamont, and E. Perkins, “Disruption of nucleocytoplasmic trafficking of cylin DI and topoisomerase II by sanguinarine,” BMC Cell Biology, vol. 7, article 13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. M. M. Chaturvedi, A. Kumar, B. G. Darnay, G. B. N. Chainy, S. Agarwal, and B. B. Aggarwal, “Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation,” Journal of Biological Chemistry, vol. 272, no. 48, pp. 30129–30134, 1997. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Sun, C. Liu, N. Nadiminty et al., “Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion,” Prostate, vol. 72, no. 1, pp. 82–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. D. G. Li, Z. R. Wang, and H. M. Lu, “Pharmacology of tetrandrine and its therapeutic use in digestive diseases,” World Journal of Gastroenterology, vol. 7, no. 5, pp. 627–629, 2001. View at Google Scholar · View at Scopus
  122. L. T. Ng, L. C. Chiang, Y. T. Lin, and C. C. Lin, “Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines,” American Journal of Chinese Medicine, vol. 34, no. 1, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. P. L. Kuo and C. C. Lin, “Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells,” Life Sciences, vol. 73, no. 2, pp. 243–252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. L. H. Meng, H. Zhang, L. Hayward, H. Takemura, R. G. Shao, and Y. Pommier, “Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G 1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1,” Cancer Research, vol. 64, no. 24, pp. 9086–9092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. X. Li, B. Su, R. Liu, D. Wu, and D. He, “Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells,” Journal of Surgical Research, vol. 166, no. 1, pp. e45–e51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. B. C. He, J. L. Gao, B. Q. Zhang et al., “Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer,” Molecular Pharmacology, vol. 79, no. 2, pp. 211–219, 2011. View at Google Scholar
  127. J. M. Wu, Y. Chen, J. C. Chen, T. Y. Lin, and S. H. Tseng, “Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice,” Cancer Letters, vol. 287, no. 2, pp. 187–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. S. M. Yoo, S. H. Oh, S. J. Lee et al., “Inhibition of proliferation and induction of apoptosis by tetrandrine in HepG2 cells,” Journal of Ethnopharmacology, vol. 81, no. 2, pp. 225–229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. J. H. Lee, G. H. Kang, K. C. Kim et al., “Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells,” International Journal of Oncology, vol. 21, no. 6, pp. 1239–1244, 2002. View at Google Scholar · View at Scopus
  130. Y. L. Lai, Y. J. Chen, T. Y. Wu et al., “Induction of apoptosis in human leukemic U937 cells by tetrandrine,” Anti-Cancer Drugs, vol. 9, no. 1, pp. 77–81, 1998. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Chen, J. C. Chen, and S. H. Tseng, “Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats,” International Journal of Cancer, vol. 124, no. 10, pp. 2260–2269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. K. H. Chang, H. F. Liao, H. H. Chang et al., “Inhibitory effect of tetrandrine on pulmonary metastases in CT26 colorectal adenocarcinoma-bearing BALB/c mice,” American Journal of Chinese Medicine, vol. 32, no. 6, pp. 863–872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. L. W. Fu, Y. M. Zhang, Y. J. Liang, X. P. Yang, and Q. C. Pan, “The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells,” European Journal of Cancer, vol. 38, no. 3, pp. 418–426, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. X. Zhu, M. Sui, and W. Fan, “In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel,” Anticancer Research, vol. 25, no. 3, pp. 1953–1962, 2005. View at Google Scholar · View at Scopus
  135. L. Fu, Y. Liang, L. Deng et al., “Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 4, pp. 349–356, 2004. View at Publisher · View at Google Scholar · View at Scopus
  136. Y. Zhang, C. Wang, H. Wang, K. Wang, Y. Du, and J. Zhang, “Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo,” Cancer Letters, vol. 304, no. 1, pp. 21–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  137. J. Wei, B. Liu, L. Wang, X. Qian, Y. Ding, and L. Yu, “Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 5, pp. 703–711, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. E. Iorns, C. J. Lord, and A. Ashworth, “Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization,” Biochemical Journal, vol. 417, no. 1, pp. 361–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. J. Yu, F. Liu, M. Sun et al., “Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinoma cells by tetrandrine,” Cancer Biotherapy and Radiopharmaceuticals, vol. 26, no. 4, pp. 437–442, 2011. View at Google Scholar
  140. K. H. Chang, M. L. Chen, H. C. Chen, Y. W. Huang, T. Y. Wu, and Y. J. Chen, “Enhancement of radiosensitivity in human glioblastoma U138MG cells by tetrandrine,” Neoplasma, vol. 46, no. 3, pp. 196–200, 1999. View at Google Scholar · View at Scopus
  141. Y. Chen, J. C. Chen, and S. H. Tseng, “Effects of tetrandrine plus radiation on neuroblastoma cells,” Anticancer Research, vol. 29, no. 8, pp. 3163–3171, 2009. View at Google Scholar · View at Scopus
  142. X. C. Sun, H. Y. Cheng, Y. X. Deng, R. G. Shao, and J. Ma, “Tetrandrine: a potent abrogator of G2 checkpoint function in tumor cells and its mechanism,” Biomedical and Environmental Sciences, vol. 20, no. 6, pp. 495–501, 2007. View at Google Scholar · View at Scopus
  143. X. Sun, R. Xu, Y. Deng et al., “Effects of tetrandrine on apoptosis and radiosensitivity of nasopharyngeal carcinoma cell line CNE,” Acta Biochimica et Biophysica Sinica, vol. 39, no. 11, pp. 869–878, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. J. A. McCubrey, J. Bäsecke, M. Cervello, A. M. Martelli, and R. A. Franklin, “GSK-3β is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity,” Cancer Biology and Therapy, vol. 7, no. 7, p. 1079, 2008. View at Google Scholar · View at Scopus
  145. X. L. Chen, K. H. Ren, H. W. He et al., “Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis,” Cancer Biology and Therapy, vol. 7, no. 7, pp. 1073–1078, 2008. View at Google Scholar
  146. C. Liu, K. Gong, X. Mao, and W. Li, “Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma,” International Journal of Cancer, vol. 129, no. 6, pp. 1519–1531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. S. H. Oh and B. H. Lee, “Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release,” Biochemical Pharmacology, vol. 66, no. 5, pp. 725–731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  148. H. S. Cho, S. H. Chang, Y. S. Chung et al., “Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells,” Journal of Veterinary Science, vol. 10, no. 1, pp. 23–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. A. K. Larsen, L. Grondard, J. Couprie et al., “The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II,” Biochemical Pharmacology, vol. 46, no. 8, pp. 1403–1412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  150. D. Lamoral-Theys, C. Decaestecker, V. Mathieu et al., “Lycorine and its derivatives for anticancer drug design,” Mini-Reviews in Medicinal Chemistry, vol. 10, no. 1, pp. 41–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Chen, J. Wang, L. Lin et al., “Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer,” Molecular Cancer Therapeutics, vol. 11, no. 2, pp. 277–287, 2011. View at Google Scholar
  152. Y. B. Ji, S. Y. Gao, C. F. Ji, and X. Zou, “Induction of apoptosis in HepG2 cells by solanine and Bcl-2 protein,” Journal of Ethnopharmacology, vol. 115, no. 2, pp. 194–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. X. M. Li, L. Z. Li, and S. L. Chen, “Inhibitory effects of sophocarpine on animal tumors,” Acta Pharmacologica Sinica, vol. 5, no. 2, pp. 125–130, 1984. View at Google Scholar · View at Scopus
  154. J. Jiang and C. Hu, “Evodiamine: a novel anti-cancer alkaloid from evodia rutaecarpa,” Molecules, vol. 14, no. 5, pp. 1852–1859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Q. Pei, “A review of pharmacology and clinical use of piperine and its derivatives,” Epilepsia, vol. 24, no. 2, pp. 177–182, 1983. View at Google Scholar · View at Scopus
  156. S. C. Lahiri and N. K. Dutta, “Berberine and chloramphenicol in the treatment of cholera and severe diarrhoea,” Journal of the Indian Medical Association, vol. 48, no. 1, pp. 1–11, 1967. View at Google Scholar · View at Scopus
  157. D. P. Bezerra, F. O. De Castro, A. P. N. N. Alves et al., “In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine,” Journal of Applied Toxicology, vol. 28, no. 2, pp. 156–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. M. J. Hu, H. Zeng, Y. L. Wu et al., “Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice,” Chinese Journal of Digestive Diseases, vol. 6, no. 2, pp. 68–71, 2005. View at Publisher · View at Google Scholar · View at Scopus
  159. J. J. Lu, W. Pan, Y. J. Hu et al., “Multi-target drugs: the trend of drug research and development,” PLoS ONE, vol. 7, no. 6, Article ID e40262, 2012. View at Google Scholar
  160. J. J. Lu, Y. J. Cai, and J. Ding, “Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells,” Molecular and Cellular Biochemistry, vol. 354, no. 1-2, pp. 247–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. J. J. Lu, S. M. Chen, X. W. Zhang, J. Ding, and L. H. Meng, “The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells,” Investigational New Drugs, vol. 29, no. 6, pp. 1276–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Zhu, X. W. Liu, W. J. Ding et al., “Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L,” Cancer Letters, vol. 297, no. 2, pp. 155–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. J. J. Lu, L. H. Meng, U. T. Shankavaram et al., “Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells,” Biochemical Pharmacology, vol. 80, no. 1, pp. 22–30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. S. Li, Z. Ji, M. Zou, X. Nie, Y. Shi, and G. Cheng, “Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine,” AAPS PharmSciTech, vol. 12, no. 3, pp. 1011–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. Q. Tan, S. Liu, X. Chen et al., “Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability,” AAPS PharmSciTech, vol. 13, no. 2, pp. 534–547, 2012. View at Google Scholar
  166. J. Tang, Y. Feng, S. Tsao, N. Wang, R. Curtain, and Y. Wang, “Berberine and Coptidis Rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations,” Journal of Ethnopharmacology, vol. 126, no. 1, pp. 5–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. E. Chan, “Displacement of bilirubin from albumin by berberine,” Biology of the Neonate, vol. 63, no. 4, pp. 201–208, 1993. View at Google Scholar · View at Scopus
  168. T. Y. K. Chan, “The prevalence use and harmful potential of some Chinese herbal medicines in babies and children,” Veterinary and Human Toxicology, vol. 36, no. 3, pp. 238–240, 1994. View at Google Scholar · View at Scopus
  169. R. K. S. Dogra, S. Khanna, and R. Shanker, “Immunotoxicological effects of piperine in mice,” Toxicology, vol. 196, no. 3, pp. 229–236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  170. M. B. Daware, A. M. Mujumdar, and S. Ghaskadbi, “Reproductive toxicity of piperine in Swiss albino mice,” Planta Medica, vol. 66, no. 3, pp. 231–236, 2000. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Unchern, H. Saito, and N. Nishiyama, “Selective cytotoxicity of piperine on cultured rat hippocampal neurons in comparison with cultured astrocytes: the possible involvement of lipid peroxidation,” Biological and Pharmaceutical Bulletin, vol. 20, no. 9, pp. 958–961, 1997. View at Google Scholar · View at Scopus
  172. C. S. Choy, K. P. Cheah, H. Y. Chiou et al., “Induction of hepatotoxicity by sanguinarine is associated with oxidation of protein thiols and disturbance of mitochondrial respiration,” Journal of Applied Toxicology, vol. 28, no. 8, pp. 945–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. W. H. Chan, “Embryonic toxicity of sanguinarine through apoptotic processes in mouse blastocysts,” Toxicology Letters, vol. 205, no. 3, pp. 285–292, 2011. View at Publisher · View at Google Scholar · View at Scopus